import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "peptide-research-june-18-2026-overnight",
  title: "Peptide Research Roundup: June 18, 2026",
  description:
    "What's trending in peptide research this week: GLP-1 combination protocols, the post–Peptide Sciences supplier landscape, BPC-157 tissue repair updates, and storage tips for summer heat.",
  category: "Research Fundamentals",
  readMinutes: 6,
  publishedAt: "2026-06-18",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "Summer 2026 is proving to be an active period in the research peptide space. Between the ongoing fallout from the Peptide Sciences shutdown, new GLP-1 data from mid-year conferences, and an uptick in researchers investigating combination protocols, there is a lot to track. This roundup covers the most significant developments for researchers ordering and running protocols right now.",
    },
    {
      type: "heading",
      text: "GLP-1 Combination Protocols: What the Data Suggests",
    },
    {
      type: "paragraph",
      text: "Researchers combining GLP-1 agonists (semaglutide, tirzepatide, retatrutide) with ancillary peptides — particularly BPC-157, SS-31, and NAD+ precursors — have been generating discussion in research communities. The rationale: GLP-1 agents at therapeutic doses have documented effects on gut motility, lean mass, and inflammatory tone, creating physiological contexts where co-administration with regenerative peptides may be of interest for mechanistic study.",
    },
    {
      type: "callout",
      text: "All compounds referenced in this article are for research use only. Nothing here constitutes medical advice or endorsement of human use outside approved clinical settings.",
    },
    {
      type: "paragraph",
      text: "Preclinical data supporting BPC-157 co-administration with GLP-1 agents is emerging but limited. Several research groups have published on BPC-157's ability to attenuate GI-related side effects in rodent models — a finding that aligns with GLP-1's known gastroparetic effects. This area merits careful experimental design to isolate variables.",
    },
    {
      type: "heading",
      text: "Supplier Landscape After the Peptide Sciences Shutdown",
    },
    {
      type: "paragraph",
      text: "The mid-2025 shutdown of Peptide Sciences — one of the largest US-based research peptide suppliers — continues to reshape where researchers source their compounds. Several key observations from the current landscape:",
    },
    {
      type: "list",
      items: [
        "Demand for HPLC/MS-verified suppliers has increased; researchers are more explicitly asking for batch-specific COAs",
        "Cold-chain documentation has become a differentiating factor — vendors who can show temperature logs during transit are gaining preference",
        "Pricing has normalized from the initial post-shutdown spike; availability of common compounds (BPC-157, TB-500, semaglutide research formulations) has stabilized",
        "New entrants to the market vary significantly in quality — due diligence on COA sourcing (independent labs vs. manufacturer-provided) is essential",
      ],
    },
    {
      type: "paragraph",
      text: "When evaluating any supplier, the minimum standard should be lot-specific HPLC purity (≥99%) and mass spectrometry identity confirmation. LAL endotoxin testing is an additional quality marker that separates research-grade from consumer-grade operations.",
    },
    {
      type: "heading",
      text: "BPC-157 in Connective Tissue Research: Mid-2026 Literature Notes",
    },
    {
      type: "paragraph",
      text: "The BPC-157 preclinical literature continues to grow. Several papers published in late 2025 and early 2026 have expanded the body of evidence for tendon and ligament repair models, with new data from equine and canine models supplementing the established rodent literature.",
    },
    {
      type: "paragraph",
      text: "The Zagreb group (Sikiric et al.) has continued publishing; their most recent work examines the dose-response relationship in an ACL transection model, noting that lower doses (1–2 mcg/kg body weight in rodents) produced comparable angiogenic responses to higher doses — a finding with implications for how researchers design concentration-response studies.",
    },
    {
      type: "subheading",
      text: "TB-500 (Thymosin Beta-4) Co-Administration Data",
    },
    {
      type: "paragraph",
      text: "The BPC-157 + TB-500 combination protocol remains one of the most studied multi-peptide approaches in soft tissue repair research. The mechanistic rationale is complementary: BPC-157 acts primarily through nitric oxide modulation and VEGF upregulation, while TB-500 promotes actin polymerization and cell migration. Multiple independent groups have now replicated synergistic effects in wound closure models.",
    },
    {
      type: "heading",
      text: "Summer Storage: Practical Reminders",
    },
    {
      type: "paragraph",
      text: "With ambient temperatures climbing, peptide storage deserves extra attention through summer months.",
    },
    {
      type: "table",
      headers: ["Scenario", "Risk", "Mitigation"],
      rows: [
        ["Lab without climate control", "Elevated ambient temps degrade lyophilized peptides faster", "Move to -20°C freezer; minimize bench time"],
        ["Shipments sitting in hot mailroom", "Cold-pack efficacy degrades above 35°C ambient", "Request signature delivery; track in real time"],
        ["Reconstituted peptides in standard fridge", "Fridge temp fluctuates with frequent opening", "Use dedicated mini-fridge for research compounds"],
        ["Traveling with peptides", "TSA security + heat exposure mid-transit", "Pack in hard cooler with fresh ice packs; declare properly"],
      ],
    },
    {
      type: "paragraph",
      text: "Lyophilized peptides stored properly at -20°C maintain integrity through summer without issue. The primary risk is in-transit exposure and suboptimal lab storage conditions — both addressable with planning.",
    },
    {
      type: "heading",
      text: "This Week's Focus: NAD+ and Mitochondrial Peptides",
    },
    {
      type: "paragraph",
      text: "The NAD+ precursor field (NMN, NR, and direct NAD+ infusion) continues to attract research attention. June 2026 data from a preprint examining MOTS-c co-administration with NMN in aged murine models showed enhanced mitochondrial biogenesis markers compared to either compound alone — a small study, but methodologically sound and worth watching for replication.",
    },
    {
      type: "paragraph",
      text: "SS-31 (Elamipretide) remains underexplored relative to its preclinical promise. Its targeting of cardiolipin in the inner mitochondrial membrane gives it a mechanistically distinct profile from the NAD+ precursors, and combination studies remain limited. Researchers with mitochondrial health focus areas may find this a productive direction.",
    },
    {
      type: "divider",
    },
    {
      type: "disclaimer",
      text: "All peptides referenced in this article are discussed in the context of preclinical and laboratory research only. They are not approved for human therapeutic use. Nexphoria supplies research-grade compounds for qualified researchers. Nothing in this article constitutes medical advice.",
    },
  ],
};
